BAJAJ HEALTHCARE LIMITED

Bajaj Healthcare Limited held its Q1 FY27 earnings conference call on July 21, 2026, where management discussed the company's financial performance and strategic initiatives. Management reported a revenue of INR 165.6 crores for the quarter, reflecting an 11.3% year-on-year growth. Gross profit increased to INR 80.4 crores, with a gross margin of 48.3%. The company highlighted its focus on expanding its API business, particularly in high-value segments like peptides and oncology. Management noted the successful completion of bioequivalence studies for Suvorexant Tablets and the launch of Cenobamate Tablets, marking significant regulatory milestones. The company also mentioned plans for a new peptide manufacturing facility and an R&D center expansion. Management guided toward a revenue growth rate of 10% to 15% for FY27. The call concluded with a Q&A session addressing various operational and financial queries from analysts.

Management emphasized growth and strategic advancements in the business.